Wanbury is a pharmaceutical company that makes its living from two sides of the same coin: it manufactures bulk drug ingredients (the chemical raw materials for medicines) for export to generic drugmakers worldwide, and it sells finished branded medicines to doctors and chemists across India. The company was born in 1990 as Pearl Organics, built its first factory in 1992, and grew through a series of acquisitions - notably buying a Sandoz subsidiary in 1995 to enter the branded formulations business and a USFDA-approved plant in Tanuku in 2006 to scale its manufacturing muscle. The recurring approach that explains everything else is a relentless focus on owning the chemistry: it picks a handful of chronic-disease molecules, captures double-digit global market share in each, and then uses the cash and capabilities from that export engine to rebuild a domestic branded franchise, all while climbing the regulatory ladder in the world’s toughest markets.
Business segments
Two engines that feed each other - a global API export powerhouse that supplies the raw chemistry for blockbuster generic drugs, and a domestic branded formulations business rebuilt on the same manufacturing backbone.
1. Active Pharmaceutical Ingredients: the global chemistry engine
Wanbury is one of the world’s largest makers of Metformin and Sertraline by market share, selling bulk drug ingredients to generic pharmaceutical companies in over 50 countries from two USFDA-approved factories.
- One of the biggest in the world for its top molecules - the company holds roughly 10% of the ~75,000-tonne global market for Metformin (the diabetes drug), about 30% of the ~680-tonne market for Sertraline (an antidepressant), and around 11% of the ~550-tonne market for Tramadol (a painkiller), which together give it pricing influence even in highly competitive commodity-API markets.
- Exports are the mainstay - the company earns better realisations than it would selling into less stringent markets.
- Two plants, one purpose - the Tanuku site in Andhra Pradesh is the workhorse with 400 kilolitres of reactor capacity across 18 acres making six molecules plus a newly launched anaesthetic, while the smaller Patalganga plant near Mumbai is a dedicated Metformin facility with 96 kilolitres of capacity; both carry approvals from the US FDA, the European EDQM, and Brazil’s ANVISA, which is what opens the door to the world’s largest generic buyers.
- Regulatory approvals are the moat - the company holds 70 active drug master filings globally, including 21 approved in the US and 8 in Europe, and its Patalganga plant passed its sixth USFDA inspection in June 2024 with zero observations, meaning no compliance gaps were found.
- New molecules are deliberately chosen - the pipeline targets mid-size molecules where the company can aim for double-digit market share, fits what its existing marquee clients already want to buy, and can deliver gross margins around 50%; a high-potency anaesthetic API was commercialised in early 2026 and shipped to a European customer within months of launch.
2. Domestic branded formulations: the India rebuild
A fully outsourced branded-medicines business selling acute-care drugs through a field force of over 300 representatives to 30,000-plus doctors, rebuilt after a debt-driven brand sale and now breaking even.
- Bought, not built from scratch - the formulations business began in 1995 when Wanbury acquired Wander Limited, a former Sandoz division, giving it an immediate portfolio of established brands and a sales force rather than starting cold.
- Outsourced manufacturing keeps it asset-light - unlike the API business, formulations are made entirely by third-party manufacturers, so the company can scale up or down without owning factories, focusing its capital on the API plants instead.
- The cold-and-cough franchise is the anchor - the Coriminic brand achieved 120% growth to a value of ₹22 crore in FY22, and the portfolio is built around acute therapies like anti-infectives, pain management, and nutritional supplements that generate frequent repeat prescriptions.
- A gynaecology comeback via iron supplements - after selling its earlier women’s-health brand C Pink to Cipla in 2020 to repay debt, the company re-entered the segment in 2025 with Wanbury C-RED, a liposomal iron tablet for pregnancy-related anaemia, launched first in North India with plans to go national.
- The strategy is to move from acute to chronic - upcoming launches target paediatrics, dermatology, cardiology, and diabetes, which would shift the mix toward higher-value chronic prescriptions and improve the productivity of the existing field force calling on the same doctors.
Group structure and partners
A lean holding structure with four overseas subsidiaries - most now wound down or settled - and a freshly incorporated Indian subsidiary to enter skin health.
- Overseas entities are largely legacy - the company has subsidiaries in the Netherlands, Spain, the UAE, and China; the Spanish unit Cantabria Pharma, acquired in 2007 to sell branded generics in Europe, is under liquidation, and all related bank guarantees and loan obligations were fully settled by FY24.
- A new Indian subsidiary targets dermatology - in June 2026, the board approved incorporating Wanbury Skin Health Limited, with Wanbury holding 82% and subscribing to 41,000 equity shares, signalling a dedicated vehicle for the planned dermatology push in the domestic formulations business.